BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/24/2022 1:16:16 PM | Browse: 581 | Download: 1135
Publication Name World Journal of Gastroenterology
Manuscript ID 74896
Country Italy
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Patient-derived organoids for therapy personalization in inflammatory bowel diseases
Manuscript Source Invited Manuscript
All Author List Marianna Lucafò, Antonella Muzzo, Martina Marcuzzi, Lorenzo Giorio, Giuliana Decorti and Gabriele Stocco
Funding Agency and Grant Number
Corresponding Author Giuliana Decorti, MD, Associate Professor, Advanced Translational Diagnostics Laboratory, Institute for Maternal and Child Health-IRCCS “Burlo Garofolo”, Via dell’Istria 65/1, Trieste 34137, Italy. giuliana.decorti@burlo.trieste.it
Key Words Inflammatory bowel disease; Organoids; Intestinal epithelium; 3D cell cultures; Personalized medicine
Core Tip Intestinal organoids have helped to unveil knowledge about inflammatory bowel diseases pathogenesis, focusing on the genetic and epigenetic factors involved in the onset of these diseases, the altered intestinal epithelial cell (IEC) functions and the interplay between IECs and other surrounding cells, including immune cells and the intestinal bacteria. Intestinal organoids are currently being evaluated in pre-clinical studies as pharmacological tools to better understand the specific mechanisms of action of already used drugs on the IECs and to identify novel pharmacological targets and approaches.
Publish Date 2022-06-24 13:12
Citation Lucafò M, Muzzo A, Marcuzzi M, Giorio L, Decorti G, Stocco G. Patient-derived organoids for therapy personalization in inflammatory bowel diseases. World J Gastroenterol 2022; 28(24): 2636-2653
URL https://www.wjgnet.com/1007-9327/full/v28/i24/2636.htm
DOI https://dx.doi.org/10.3748/wjg.v28.i24.2636
Full Article (PDF) WJG-28-2636.pdf
Full Article (Word) WJG-28-2636.docx